Martin Sarkar, DO
Endocrinology, Diabetes & Metabolism · Frederick, MDNPI 1518005636
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $953,801 of the $1,123,567 with a category attached, or 84.9%. It is spread thinly across 32 manufacturers, the largest accounting for just 22.7%. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,707 payments — averaging $658.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$255K
- Dexcom, Inc.$185K
- Insulet Corporation$147K
- AstraZeneca$123K
- Boehringer Ingelheim$108K
- Mannkind Corporation$64K
- plus $240K from 26 others
What the payments were for
- Consulting fees$39,0713%
- Speaking & faculty fees$953,80185%
- Travel & lodging$93,9288%
- Food & beverage$36,5823%
- Education$1260%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 282 | $255,404 |
| Dexcom, Inc. | 245 | $185,446 |
| Insulet Corporation | 277 | $147,386 |
| AstraZeneca(2 entities) | 175 | $122,721 |
| Boehringer Ingelheim | 146 | $108,294 |
| Mannkind Corporation | 165 | $63,983 |
| Valeritas, Inc. | 80 | $49,280 |
| Lilly USA, LLC | 73 | $40,759 |
| Sanofi-aventis U.S. LLC | 48 | $37,509 |
| Xeris Pharmaceuticals, Inc. | 76 | $23,315 |
| Intuity Medical Inc | 9 | $22,825 |
| Cequr Corporation | 9 | $21,901 |
| Ascendis Pharma Endocrinology Inc | 14 | $18,497 |
| Zealand Pharma US, Inc. | 32 | $8,741 |
| Bayer | 19 | $6,303 |
| Fresenius Kabi USA, LLC | 7 | $5,090 |
| Ascensia Diabetes Care US Inc. | 11 | $4,215 |
| Corcept Therapeutics | 10 | $479 |
| Tandem Diabetes Care, Inc. | 5 | $309 |
| Medtronic(2 entities) | 7 | $298 |
| Baxter Healthcare | 3 | $295 |
| Sanofi | 1 | $245 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Antares Pharma, Inc. | 2 | $39 |
| Amgen | 2 | $35 |
| BETA Bionics, Inc. | 1 | $32 |
| Sequel Med Tech, LLC | 1 | $28 |
| Companion Medical, Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Tolmar, Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$145,232
- Omnipod$141,594
- RYBELSUS$130,234
- FARXIGA$119,421
- DEXCOM G7 GSS (161)$99,173
- Ozempic$90,760
- DEXCOM G6 TRANSMITTER$63,085
- AFREZZA$57,116
- V-GO$56,450
- DEXCOM STELO GLUCOSE BIOSENSOR$37,834
- TZIELD$33,044
- Pogo Automatic Blood Glucose Monitoring System$22,618
- CeQur Simplicity$21,872
- GVOKE HYPOPEN$21,133
- Tresiba$20,345
- Yorvipath$18,355
- DEXCOM CGM$13,042
- DEXCOM G6 CGM SYSTEM$6,821
- Xultophy 100/3.6$6,630
- Kerendia$5,944
How this compares
$1,123,567 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 203 | $390,514 |
| JardianceEmpagliflozin | 111 | $173,372 |
| TrulicityDulaglutide | 85 | $151,691 |
| MounjaroTirzepatide | 75 | $136,023 |
| FarxigaDapagliflozin Propanediol | 93 | $134,068 |
| AfrezzaInsulin Regular, Human | 39 | $96,577 |
| Tresiba Flextouch U-100Insulin Degludec | 84 | $59,493 |
| RybelsusSemaglutide | 28 | $57,919 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 33 | $46,577 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $46,344 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $39,107 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $34,574 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $28,449 |
| FiaspInsulin Aspart (Niacinamide) | 18 | $26,821 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $23,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $255,404 | $488,621292 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $40,759 | $293,926179 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $108,294 | $222,689152 claims |
| AstraZenecaFarxiga | $122,721 | $134,06893 claims |
| Mannkind CorporationAfrezza | $63,983 | $96,57739 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $37,509 | $28,44920 claims |
| Cequr CorporationCequr Simplicity | $21,901 | $21,18448 claims |
| AbbVieSynthroid | $17 | $6,83386 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $3,846356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Frederick
- Majd HakimFrederick$142K
- Kayur BhavsarFrederick$7K
- Pratik ShahFrederick$5K
- Daniel GozziSuitland$1.2M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.